BUZZ-Novo falls on U.S. President Trump's lower Ozempic price comments
I'm PortAI, I can summarize articles.
Shares of Novo Nordisk fell approximately 5% following U.S. President Donald Trump's comments about lowering the price of Ozempic, the company's leading weight-loss drug. Analyst Per Hansen noted that there was nothing new in Trump's statements and confirmed that price negotiations are ongoing, with results expected in the coming months. If the losses persist, it could mark Novo's worst trading day since August.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments